Healthcare

SHAPE's FY26 accounts, covering the year ended 30 June 2026, reported revenue of approximately A$1.24 billion, up from the prior year, and net profit after tax of A$31.7 million.

The company’s focus remains on expanding its product portfolio while continuing to grow its existing installed base.

Echo IQ advised the market in September 2026 that the United States Food and Drug Administration issued a Not Substantially Equivalent determination for the initial 510(k) submission of EchoSolv HF.

HealthCo Healthcare and Wellness REIT released its FY26 results in August 2026. Funds from operations were reported at 4.0 cents per unit, compared with 6.6 cents per unit in FY25. Underlying funds from operations, including the trust’s share of an associated healthcare fund, were …

The company’s FY2026 results highlighted higher revenue, improved profitability and growth in contracted work. Future performance will depend on the conversion of contracted opportunities, clinical trial activity and continuedDemandfor digital assessment solutions.

Australian Clinical Labs Limited (ASX:ACL) operates a national pathology services network providing diagnostic testing across Australia. The company’s FY26 results reflected a period of operational improvement, with underlyingEarningsincreasing despite a challenging revenue environment affected by lower market growth and changes in Medicare-funded services.

Following regulatory clearances and early commercial activity, Artrya has shifted its focus towards expanding adoption of its technology, particularly in the United States market. The company’s progress will depend on converting commercial opportunities intoRecurring Revenueand expanding its customer base.